Get in Touch
ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.
Rapid Startup Early Phase Obesity Study Across Six ERG Sites
Six ERG clinical sites selected to conduct multicenter Phase IIa clinical trial evaluating a novel investigational therapy for weight loss. The study was awarded exclusively to ERG based on commitments to compressed startup timelines and enrollment of 125 patients within 8 weeks.
Key Elements
- Phase IIa Proof-of-Concept
- Randomized, Double-blind, Placebo-controlled Study
- 2 Part Dose Escalation: SAD & MAD
- Total trial duration: 19 weeks
- IP: oral tablet
124
Participants
6
Sites
5 Weeks
Enrollment Completed
Enrollment Details
- BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 + at least 1 comorbidity
- Nonsmokers
- 18-75 years of age
Scientific Leadership
Our Obesity Task Force is a cross-functional team of Metabolism Subject Matter Experts focused on strategic execution including protocol design, site selection, recruitment, and regulatory alignment.
Complex Testing Onsite
Unified Site Methodology, our established standardized procedures (anthropometrics, indirect calorimetry) across all sites, ensure high quality data collection.
Integrated Cross-Site Project
ERG readily support sponsors in the design and execution of obesity clinical trials with a portfolio of 20 wholly owned sites with scalable infrastructure spanning major metropolitan area and regional hubs.
